The complaint
The case is Shionogi Inc. v. Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India LLP, and Slayback Pharma LLC, No. 2:26-cv-14715 (D.N.J.), a 35-page complaint filed November 13, 2026, ECF No. 1. Shionogi says it is a Delaware corporation with a place of business in Florham Park, New Jersey. The complaint says its allegations rest on knowledge as to Shionogi's own actions and on information and belief as to all other matters. It alleges, on information and belief, that Azurity Pharmaceuticals, Inc. is a Delaware company with a place of business in Woburn, Massachusetts, and a place of business in New Jersey; that Azurity Pharmaceuticals India LLP is an Indian company with its principal place of business in Hyderabad, India, and a wholly owned subsidiary of Azurity; and that Slayback Pharma LLC is a Delaware company with a regular and established place of business in Princeton, New Jersey, which Azurity announced it had acquired on September 27, 2023.
The complaint says that, as publicly announced on December 22, 2025, Shionogi agreed to acquire the global RADICAVA ORS business from the product's prior owner, and that as of April 1, 2026, it acquired the U.S. RADICAVA ORS assets, including NDA No. 215446 and its Orange Book-listed patents. It says the FDA approved RADICAVA ORS, an edaravone oral suspension at 105 mg/5 mL, on May 12, 2022, and that its Orphan Drug Exclusivity expires May 12, 2029. It lists twenty related RADICAVA ORS patent actions in the district, including In re Radicava ORS, No. 2:25-cv-03326, filed April 25, 2025; No. 2:26-cv-00559, filed January 16, 2026, a suit by the prior owner against the same three defendants; and Shionogi Inc. v. Azurity Pharmaceuticals, Inc. et al., No. 2:26-cv-09805, filed August 3, 2026.
The application and the notice letters
The complaint alleges, on information and belief, that Azurity holds 505(b)(2) NDA No. 221059 for an edaravone product for amyotrophic lateral sclerosis, relying on RADICAVA ORS as the reference listed drug. It describes four notice letters. It alleges, on information and belief, that Shionogi's predecessor received a letter dated December 8, 2025, purporting to provide notice of a Paragraph IV certification on six of the patents for "Edaravone Oral Solution, 105 mg / 5 mL." It says Shionogi received letters dated June 16, 2026, on the '586 patent, and September 30, 2026, on all seven patents, for the same 105 mg/5 mL product, and a letter dated October 16, 2026, on all seven patents, which it calls the 90 mg / 5 mL Reformulation Notice Letter, stating that the defendants seek approval to market a 90 mg/5 mL edaravone formulation.
The complaint says the prior owner sued the defendants within 45 days of receiving the first letter, on January 16, 2026, in No. 2:26-cv-00559, triggering a 30-month stay under 21 U.S.C. § 355(c)(3)(C). It alleges, on information and belief, that the FDA granted tentative approval to the 105 mg/5 mL product on or around July 17, 2026, that the defendants then amended the application, triggering a recertification under 21 C.F.R. § 314.60(f)(1)(iii), and that the defendants no longer seek approval of the 105 mg/5 mL product. Shionogi says it brought this action within 45 days of its October 20, 2026 receipt of the reformulation letter and that it is entitled to a 30-month stay of FDA approval beginning October 20, 2026. It says the letter provides no substantive factual basis for noninfringement, that its counsel reviewed portions of the application under an Offer of Confidential Access, and that it has not received samples of the proposed product or its edaravone ingredient.
The complaint alleges, on information and belief, that the three defendants operate as integrated units of the same corporate group, acting as agents or alter egos of one another, and that Slayback personnel and its Princeton facility supported the application. It also alleges, on information and belief, that subject matter disclosed in Slayback's U.S. Patents 12,343,330 and 12,491,178, both titled Stable Pharmaceutical Compositions of Edaravone, tracks the proposed product, and that those patents are now assigned to Azurity.
The patents
The complaint asserts seven patents, each titled Edaravone suspension for oral administration and listed in the Orange Book for NDA No. 215446, and says Shionogi owns each of them: U.S. Patent 10,987,341, issued April 27, 2021; U.S. Patent 11,241,416, issued February 8, 2022; U.S. Patent 11,478,450, issued October 25, 2022; U.S. Patent 11,826,352, issued November 28, 2023; U.S. Patent 11,957,660, issued April 16, 2024; U.S. Patent 12,285,409, issued April 29, 2025; and U.S. Patent 12,599,586, issued April 14, 2026.
Claim 1 of the '586 patent covers an edaravone suspension for human oral administration comprising water, edaravone particles comprising edaravone and dispersed in the water, and a dispersant that maintains the edaravone particles in a solid particle state in the water, prepared by mixing edaravone particles with a D50 particle size of 10 to 50 micrometers and a D90 particle size of 50 to 200 micrometers with the water and the dispersant, where the particles have a dissolution rate of 80 percent or more 30 minutes into a dissolution test under Dissolution Test Method 2 of the Japanese Pharmacopoeia.
The counts and the prayer
Each of the seven counts covers one patent. Each alleges that the defendants infringed under 35 U.S.C. § 271(e)(2) by submitting the application, and alleges, on information and belief, that the proposed product infringes at least independent claim 1 of the patent, literally and/or under the doctrine of equivalents, that its commercial manufacture, use, sale, offer for sale, or importation would infringe under 35 U.S.C. § 271(a), (b), and/or (c), and that the defendants had actual and constructive notice of the patent before filing the application. Each count also alleges irreparable harm without an adequate remedy.
The prayer asks for a judgment of infringement under 35 U.S.C. § 271(e)(2); a judgment that commercial activity with the proposed product will infringe, induce, and/or contribute to infringement; an order under 35 U.S.C. § 271(e)(4)(A) that any FDA approval of NDA No. 221059 take effect no earlier than the expiration of the patents, including extensions, adjustments, and exclusivities; preliminary and permanent injunctions against commercial activity with any drug product, or its use, claimed in the patents before the patents expire, including any extensions, adjustments, and periods of exclusivity, including Orphan Drug Exclusivity; an exceptional-case declaration with reasonable expenses, including attorneys' fees, under 35 U.S.C. § 285; costs; and other relief.
What to watch next
Watch for the defendants' response and for any consolidation or coordination with No. 2:26-cv-09805, No. 2:26-cv-00559, and the other RADICAVA ORS actions in the district. The case can end at any time, including by settlement or voluntary dismissal.